Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Equillium Inc (EQ)

Equillium Inc (EQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,384
  • Shares Outstanding, K 60,893
  • Annual Sales, $ 41,100 K
  • Annual Income, $ -8,070 K
  • EBIT $ -24 M
  • EBITDA $ -25 M
  • 60-Month Beta 1.87
  • Price/Sales 15.41
  • Price/Cash Flow N/A
  • Price/Book 2.98

Options Overview Details

View History
  • Implied Volatility 927.83% (+303.66%)
  • Historical Volatility 95.36%
  • IV Percentile 92%
  • IV Rank 67.29%
  • IV High 1,340.64% on 11/19/25
  • IV Low 78.53% on 12/18/25
  • Expected Move (DTE 8) 0.1700 (10.83%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 3
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 2,238
  • Open Int (30-Day) 3,689
  • Expected Range 1.4000 to 1.7400

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.16
  • Growth Rate Est. (year over year) +624,475.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.0500 +52.86%
on 01/15/26
1.6199 -0.92%
on 02/12/26
+0.4550 (+39.57%)
since 01/12/26
3-Month
0.7562 +112.25%
on 11/14/25
1.7000 -5.59%
on 12/26/25
+0.6810 (+73.70%)
since 11/12/25
52-Week
0.2700 +494.44%
on 06/24/25
2.3500 -31.70%
on 09/05/25
+0.7270 (+82.80%)
since 02/12/25

Most Recent Stories

More News
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 1.6600 (+7.10%)
Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...

EQ : 1.6600 (+7.10%)
Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update

Closed financing of up to $50 million; initial tranche of $30 million provides runway through 2027 Hosted key opinion leader event highlighting the important role of the Aryl Hydrocarbon Receptor...

EQ : 1.6600 (+7.10%)
Equillium to Participate in Upcoming Investor Conferences

LA JOLLA, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...

EQ : 1.6600 (+7.10%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LA JOLLA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced...

EQ : 1.6600 (+7.10%)
Equillium to Host Ulcerative Colitis KOL Event on November 5, 2025

LA JOLLA, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...

EQ : 1.6600 (+7.10%)
Equillium Announces Board Restructuring and Biocon Agreement Termination

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

EQ : 1.6600 (+7.10%)
Equillium Announces Leadership and Corporate Updates

LA JOLLA, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics...

EQ : 1.6600 (+7.10%)
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that on August 29, 2025, the Compensation Committee...

EQ : 1.6600 (+7.10%)
Equillium to Participate in the Cantor Global Healthcare Conference 2025

Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will participate in a fireside...

EQ : 1.6600 (+7.10%)

Business Summary

Equillium, Inc. is a biotechnology company. It develops products for autoimmune and inflammatory disorders. The company's product pipeline consists of EQ001 which is in clinical-stage. Equillium, Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 1.6800
2nd Resistance Point 1.6300
1st Resistance Point 1.5900
Last Price 1.6600
1st Support Level 1.5000
2nd Support Level 1.4500
3rd Support Level 1.4100

See More

52-Week High 2.3500
Last Price 1.6600
Fibonacci 61.8% 1.5554
Fibonacci 50% 1.3100
Fibonacci 38.2% 1.0646
52-Week Low 0.2700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar